Company news

Savara, Inc. news in 2024

Savara, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 17, 2024

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

November 21, 2024

Savara Announces Participation in Upcoming Healthcare Conferences

November 12, 2024

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

November 3, 2024

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

October 21, 2024

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

September 30, 2024

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

September 26, 2024

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

September 23, 2024

Savara to Host Analyst and Investor Webinar on September 30, 2024

September 22, 2024

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

September 7, 2024

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

August 14, 2024

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

August 11, 2024

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

June 27, 2024

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 25, 2024

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 24, 2024

Savara to Present at the Jefferies Global Healthcare Conference

May 28, 2024

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

May 18, 2024

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Savara to Present at the Citizens JMP Life Sciences Conference

May 6, 2024

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

April 7, 2024

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

March 6, 2024

Savara to Present at the Barclays 26th Annual Global Healthcare Conference

March 5, 2024

Savara to Present at Two Upcoming Healthcare Conferences

January 30, 2024

Decks in 2024